A Randomized, Comparative Study to Evaluate Efficacy and Safety of Two Injection Volumes of AbobotulinumtoxinA in Treatment of Glabellar Lines

被引:12
|
作者
Punga, Anna Rostedt [1 ]
Alimohammadi, Mohammad [2 ]
Fagrell, Dan [3 ]
Nyberg, Frida [4 ]
Rees, Diane [5 ]
Wong, Cindy [4 ]
机构
[1] Uppsala Univ, Dept Neurosci, Husargatan 3, S-75124 Uppsala, Sweden
[2] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[3] Goteborgs Plastikkirurgiska Ctr, Gothenburg, Sweden
[4] Galderma A&C, Uppsala, Sweden
[5] Zenith Healthcare Commun Ltd, Chester, Cheshire, England
关键词
TOXIN TYPE-A; DOUBLE-BLIND; BOTULINUM; DIFFUSION; RHYTIDES;
D O I
10.1097/DSS.0000000000000805
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BACKGROUNDDifferent volumes of 0.9% NaCl may be used to reconstitute abobotulinumtoxinA yielding an injection volume that ranges from 0.05 to 0.1 mL per injection point for treatment of glabellar lines.OBJECTIVETo evaluate the efficacy, safety, and subject satisfaction of 2 different injection volumes to deliver the same unit dose of abobotulinumtoxinA for treatment of glabellar lines.MATERIALS AND METHODSThis randomized comparative study was conducted using 2 different reconstitution volumes to deliver a fixed unit dose of 10 Speywood units (sU) of abobotulinumtoxinA in either 0.05 mL (labeled volume) or 0.1 mL (twofold volume) per injection point. Evaluations included wrinkle severity, neurophysiological assessment by compound muscle action potential (CMAP), and subject satisfaction.RESULTSUse of either injection volume of abobotulinumtoxinA resulted in the early onset of effect, high effectiveness, and long duration of effect. The safety profile and injection pain levels were similar in both groups. The twofold injection volume was shown to be noninferior to the labeled injection volume based on CMAP results.CONCLUSIONA twofold increase in injection volume to 0.1 mL per injection point to deliver 10 sU of abobotulinumtoxinA is effective and safe.
引用
收藏
页码:967 / 976
页数:10
相关论文
共 50 条
  • [31] DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study
    Fabi, Sabrina G.
    Cohen, Joel L.
    Green, Lawrence J.
    Dhawan, Sunil
    Kontis, Theda C.
    Baumann, Leslie
    Gross, Todd M.
    Gallagher, Conor J.
    Brown, Jessica
    Rubio, Roman G.
    DERMATOLOGIC SURGERY, 2021, 47 (01) : 48 - 54
  • [32] Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials
    Xue Li
    Changlin Sui
    Xiujuan Xia
    Xianjin Chen
    Aesthetic Plastic Surgery, 2023, 47 : 365 - 377
  • [33] A multicenter, randomized, double-blind study to evaluate the efficacy of onabotulinumtoxina (20 units) in the treatment of glabellar lines, when compared to incoboulinumtoxina (30 units)
    Moers-Carpi, Marion
    Fulford-Smith, Antony
    Tan, Kelvin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB20 - AB20
  • [34] Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials
    Li, Xue
    Sui, Changlin
    Xia, Xiujuan
    Chen, Xianjin
    AESTHETIC PLASTIC SURGERY, 2023, 47 (01) : 365 - 377
  • [35] A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines
    Ascher, B
    Zakine, B
    Kestemont, P
    Baspeyras, M
    Bougara, A
    Santini, J
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (02) : 223 - 233
  • [36] Long-Term Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines: Results From a 36-Month, Multicenter, Open-Label Extension Study
    Schlessinger, Joel
    Dover, Jeffrey S.
    Joseph, John
    Monheit, Gary
    Nelson, Diane B.
    Albright, Craig D.
    Axford-Gatley, Robert A.
    Cohen, Joel L.
    DERMATOLOGIC SURGERY, 2014, 40 (02) : 176 - 183
  • [37] Results of a large open-label safety study of daxibotulinumtoxina for injection in glabellar lines
    Guillen-Fabi, Sabrina
    Green, Jeremy B.
    Liu, Yan
    Rubio, Roman G.
    Gallagher, Conor J.
    Gross, Todd M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB98 - AB98
  • [38] A Phase III Clinical Study of the Efficacy and Safety of Botulinum Toxin Type A (MASPORT) with DYSPORT for the Treatment of Glabellar Lines
    Hedayat, Kamand
    Ehsani, Amir H.
    AESTHETIC PLASTIC SURGERY, 2024, 48 (03) : 324 - 332
  • [39] Subject Satisfaction With AbobotulinumtoxinA for Moderate-to-Severe Glabellar Lines: A Randomized, Dose-Escalation, Double-Blind Study
    Moradi, Amir
    Dayan, Steven
    Joseph, John
    Lorenc, Z. Paul
    Coleman, Kyle
    Ablon, Glynis
    Kaufman-Janette, Joely
    Cox, Sue Ellen
    Campbell, Andrew
    Munavalli, Girish
    TOXICON, 2022, 214 : S42 - S42
  • [40] A Phase III Clinical Study of the Efficacy and Safety of Botulinum Toxin Type A (MASPORT) with DYSPORT for the Treatment of Glabellar Lines
    Kamand Hedayat
    Amir H. Ehsani
    Aesthetic Plastic Surgery, 2024, 48 : 324 - 332